Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Pathologically (histologically) confirmed diagnosis of ESCC~2. Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent or metastatic disease (per American Joint Committee on Cancer 7th Edition), if there is prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy, a treatment-free interval of at least 6 months is required.~Key Exclusion Criteria:~1. Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation~2. Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC~3. Received prior therapies targeting programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1) or PD-L2~4. Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta)~5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (clinically significant recurrence requiring an additional intervention within 2 weeks of intervention)~6. Evidence of complete esophageal obstruction not amenable to treatment~7. Unintentional weight loss ≥ 5% within one month prior to randomization or Nutritional Risk Index (NRI) \< 83.5 per investigator's choice~8. Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator.~9. Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is ≥ 500 IU/mL or participants with active hepatitis C virus (HCV)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tislelizumab + Chemotherapy (Type: EXPERIMENTAL): Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~* Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W;~* Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or~* Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines
- Placebo + Chemotherapy (Type: ACTIVE_COMPARATOR): Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~* Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W;~* Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or~Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).